Curcumin inhibits glutamate release in nerve terminals from rat prefrontal cortex: Possible relevance to its antidepressant mechanism

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 7, 2011, Pages 1785-1793

  Lin, Tzu Yu ^c,d   Lu, Cheng Wei ^c   Wang, Chia Chuan ^b   Wang, Ying Chou ^a   Wang, Su Jane ^a,b  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d YUAN ZE UNIVERSITY   (Taiwan)

Author keywords

Ca v2.2 and Ca v2.1 channels; Curcumin; Depression; Glutamate release; Prefrontal cortex; Synaptosomes

Indexed keywords

2 [2 [4 (4 NITROBENZYLOXY)PHENYL]ETHYL]ISOTHIOUREA METHANESULFONATE; 4 AMINOPYRIDINE; BAFILOMYCIN A1; CALCIUM CHANNEL N TYPE; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; CALCIUM ION; CAV2.1 CHANNEL; CAV2.2 CHANNEL; CPG 37157; CURCUMIN; DANTROLENE; DEXTRO THREO BETA BENZYL OXYASPARYATE; FLUOXETINE; GLUTAMIC ACID; PROTEIN INHIBITOR; SODIUM ION; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEPOLARIZATION; DRUG ACTIVITY; DRUG EFFICACY; EVOKED RESPONSE; ION TRANSPORT; MALE; MEMBRANE STEADY POTENTIAL; MONOTHERAPY; NONHUMAN; PREFRONTAL CORTEX; RAT; SYNAPTOSOME;

4-AMINOPYRIDINE; ANIMALS; ANTIDEPRESSIVE AGENTS; CALCIUM; CURCUMIN; GLUTAMIC ACID; MALE; MEMBRANE POTENTIALS; NERVE ENDINGS; POTASSIUM CHANNEL BLOCKERS; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTOSOMES;

EID: 79961128057     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.06.012     Document Type: Article

References (59)

1. Adell A., Castro E., Celada P., Bortolozzi A., Pazos A., Artigas F. Strategies for producing faster acting antidepressants. Drug Discov Today 2005, 2005(10):578-585.
2. Akerman K.E., Scott I.G., Heikkila J.E., Heinonen E. Ionic dependence of membrane potential and glutamate receptor-linked responses in synaptoneurosomes as measured with a cyanine dye, DiS-C2-(5). J Neurochem 1987, 48:552-559.
3. Ammon H.P., Wahl M.A. Pharmacology of Curcuma longa. Planta Med 1991, 57:1-7.
4. Attwell D., Barbour B., Szatkowski M. Nonvesicular release of neurotransmitter. Neuron 1993, 375:645-653.
5. Barrie A.P., Nicholls D.G., Sanchez-Prieto J., Sihra T.S. An ion channel locus for the protein kinase C potentiation of transmitter glutamate release from guinea pig cerebrocortical synaptosomes. J Neurochem 1991, 57:1398-1404.
6. Berridge M.J. Neuronal calcium signaling. Neuron 1998, 21:13-26.
7. Blaustein M.P., Lederer W.J. Sodium/calcium exchange: its physiological implications. Physiol Rev 1999, 79:763-854.
8. Bonanno G., Giambelli R., Raiter L., Tiraboschi E., Zappettini S., Musazzi L., et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 2005, 25:3270-3279.
9. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
10. Drevets W.C. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res 2000, 126:413-431.
11. Golembiowska K., Dziubina A. Effect of acute and chronic administration of citalopram on glutamate and aspartate release in the rat orefrontal cortex. Pol J Pharmacol 2000, 52:441-448.
12. Grynkiewicz G., Poenie M., Tsien R.Y. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985, 260:3440-3450.
13. Holden C. Psychiatric drugs. Excited by glutamate. Science 2003, 300:1866-1868.
14. Kendell S.F., Krystal J.H., Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin Ther Targets 2005, 9:153-168.
15. Kessler R.C., Soukup J., Davis R.B., Foster D.F., Wilkey S.A., Van Rompay M.I., et al. The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am J Psychiatry 2001, 158:289-294.
16. Kulkarni S.K., Bhutani M.K., Bishnoi M. Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacology 2008, 201:435-442.
17. Li M., West J.W., Numann R., Murphy B.J., Scheuer T., Catterall W.A. Convergent regulation of sodium channels by protein kinase C and cAMP-dependent protein kinase. Science 1993, 261:1439-1442.
18. Li Y.C., Wang F.M., Pan Y., Qiang L.Q., Cheng G., Zhang W.Y., et al. Antidepressant-like effects of curcumin on serotonergic receptor-coupled AC-cAMP pathway in chronic unpredictable mild stress of rats. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:435-449.
19. Lin T.Y., Yang T.T., Lu C.W., Wang S.J. Inhibition of glutamate release by bupropion in rat cerebral cortex nerve terminals. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:598-606.
20. McNally L., Bhagwagar Z., Hannestad J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr 2008, 13:501-510.
21. Michael-Titus A.T., Bains S., Jeetle J., Whelpton R. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex: a possible mechanism of neuroprotection in major depression. Neuroscience 2000, 100:681-684.
22. Millan C., Sanchez-Prieto J. Differential coupling of N- and P/Q-type calcium channels to glutamate exocytosis in the rat cerebral cortex. Neurosci Lett 2002, 330:29-32.
23. Millan M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006, 110:135-370.
24. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Bio Psychiatry 2009, 65:732-741.
25. Motterlini R., Foresti R., Bassi R., Green C.J. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med 2000, 28:1301-1312.
26. Nicholls D.G. Presynaptic modulation of glutamate release. Prog Brain Res 1998, 116:15-22.
27. Nicholls D.G., Sihra T.S., Sanchez-Prieto J. Calcium-dependent and -independent release of glutamate from synaptosomes monitored by continuous fluorometry. J Neurochem 1987, 49:50-57.
28. Palucha A., Pilc A. Metabotropic glutamate receptor ligands as possible axiolytic and antidepressant drugs. Pharmacol Ther 2007, 115:116-147.
29. Pan M.H., Huang T.M., Lin J.K. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 1999, 27:486-494.
30. Paul I.A., Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci 2003, 100:250-272.
31. Pilc A., Chaki S., Nowak G., Witkin J.M. Mood disorders: regulation by metabotropic glutamate receptors. Biochem Pharmacol 2008, 75:997-1006.
32. Pittenger G., Sanacora G., Krystal J.H. The MNDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Tatgets 2007, 6:101-115.
33. Pongs O., Leicher T., Berger M., Roeper J., Bahring R., Wray D., et al. Functional and molecular aspects of voltage-gated K+ channel beta subunits. Ann N Y Acad Sci 1999, 868:344-355.
34. Prikhozhan A.V., Kovalev G.I., Raevskii K.S. Effects of antidepressive agents on glutamatergic autoregulatory presynaptic mechanism in the rat cerebral cortex. Bull Exp Biol Med 1990, 110:624-626.
35. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006, 27:24-31.
36. Raiteri L., Raiteri M., Bonanno G. Coexistence and function of different neurotransmitter transporters in the plasma membrane of CNS neurons. Prog Neurobiol 2002, 68:287-309.
37. Rehm H., Tempel B.L. Voltage-gated K+ channels of mammalian brain. FASEB J 1991, 5:164-170.
38. Sanacora G., Gueorguieva R., Epperson C.N., Wu Y.T., Appel M., Rothman D.L., et al. Subtype-specific alterations of γ-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004, 61:705-713.
39. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008, 7:426-437.
40. Sapolsky R.M. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry 2000, 48:755-765.
41. Schechter L.E., Ring R.H., Beyer C.E., Hughes Z.A., Khawaja X., Malberg J.E., et al. Innovative approaches for the development of antidepressant drugs: current and future strategies. J Am Soc Exp Neurother 2005, 2:590-611.
42. Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., Srinivas P.S.S.R. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998, 64:353-356.
43. Sihra T.S., Bogonez E., Nicholls D.G. Localized Ca2+ entry preferentially effects protein dephosphorylation, phosphorylation, and glutamate release. J Biol Chem 1992, 267:1983-1989.
44. Sihra T.S., Nichols R.A. Mechanisms in the regulation of neurotransmitter release from brain nerve terminals: current hypotheses. Neurochem Res 1993, 18:47-58.
45. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol 1999, 375:31-40.
46. Skolnick P. Modulation of glutamate receptors: strategies for the development of novel antidepressants. Amino Acids 2002, 23:153-159.
47. Srimal R.C., Dhawan B.N. Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol 1973, 25:447-452.
48. Thompson S.M., Capogna M., Scanziani M. Presynaptic inhibition in the hippocampus. Trends Neurosci 1993, 16:222-227.
49. Tibbs G.R., Barrie A.P., Van Mieghem F.J., McMahon H.T., Nicholls D.G. Repetitive action potentials in isolated nerve terminals in the presence of 4-aminopyridine: effects on cytosolic free Ca2+ and glutamate release. J Neurochem 1989, 53:1693-1699.
50. Wahlström B., Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol 1978, 43:86-92.
51. Wang S.J., Su C.F., Kuo Y.H. Fluoxetine depresses glutamate exocytosis in the rat cerebrocortical nerve terminals (synaptosomes) via inhibition of P/Q-type Ca2+ channels. Synapse 2003, 48:170-177.
52. Wang Q., Sun A.Y., Simonyi A., Jensen M.D., Shelat P.B., Rottinghaus G.E., et al. Neuroprotective mechanisms of curcumin against cerebral ischemia-induced neuronal apoptosis and behavioral deficits. J Neurosci Res 2005, 82:138-148.
53. Wang R., Xu Y., Wu H.L., Li Y.B., Li Y.H., Guo J.B., et al. The antidepressant effects of curcumin in the forced swimming test involve 5-HT1 and 5-HT2 receptors. Eur J Pharmacol 2008, 578:43-50.
54. Wang R., Li Y.B., Li Y.H., Xu Y., Wu H.L., Li X.J. Curcumin protects against glutamate excitotoxicity in rat cerebral cortical neurons by increasing brain-derived neurotrophic factor level and activating TrkB. Brain Res 2008, 1210:84-91.
55. Witkin J.M., Marek G.J., Johnson B.G., Schoepp D.D. Metabotropic glutamate receptors in the control of mood disorder. CNS Neurol Disord Drug Tatgets 2007, 6:87-100.
56. Xu Y., Ku B.S., Yao H.Y., Lin Y.H., Ma X., Zhang Y.H., et al. The effects of curcumin on depressive-like behaviors in mice. Eur J Pharmacol 2005, 518:40-46.
57. Xu Y., Ku B.S., Yao H.Y., Lin Y.H., Ma X., Zhang Y.H., et al. Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol Biochem Behav 2005, 82:200-206.
58. Zarate C.A., Quiroz J., Payne J., Manji H.K. Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull 2002, 36:35-83.
59. Zucchi R., Ronca-Testoni S. The sarcoplasmic reticulum Ca2+ channel/ryanodine receptor: modulation by endogenous effectors, drugs and disease states. Pharmacol Rev 1997, 49:1-51.